Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Hersey JC, Cates SC, Blitstein JL, Kosa KM, Santiago Rivera OJ, Contreras DA, Long VA, Singh A, Berman DA. Eat Smart, Live Strong intervention increases fruit and vegetable consumption among low-income older adults. J Nutr Gerontol Geriatr. 2015;34(1):66-80. doi: 10.1080/21551197.2015.1007199
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Kosa KM, Cates SC, Godwin SL, Ball M, Harrison RE. Effectiveness of educational interventions to improve food safety practices among older adults. J Nutr Gerontol Geriatr. 2011;30(4):369-83. doi: 10.1080/21551197.2011.623943
Pueschel SM, Rothman KJ, Ogilby JD. Birth weight of children with down's syndrome. Am J Ment Defic. 1976 Jan;80(4):442-5.